Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)

RAJAF Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.88	0.05	-	0.2
Revenue Growth (YoY)	1555.66%	-	-	-
Cost of Revenue	0.12	0.01	-	0.06
Gross Profit	0.77	0.04	-	0.14
Selling, General & Admin	0.54	0.34	0.09	0.13
Research & Development	-	0.12	0.03	-
Other Operating Expenses	-	-	-	0
Operating Expenses	0.54	0.45	0.12	0.13
Operating Income	0.23	-0.42	-0.12	0.01
Interest Expense	-0.03	-	-	-0.03
Interest & Investment Income	0	0	0	0
Other Non Operating Income (Expenses)	0	-	-	0
Pretax Income	0.2	-0.42	-0.12	-0.02
Income Tax Expense	-0.04	-	-	0
Earnings From Continuing Operations	0.24	-0.42	-0.12	-0.02
Earnings From Discontinued Operations	0.58	-0.3	-0.37	-
Net Income	0.82	-0.72	-0.49	-0.02
Net Income to Common	0.82	-0.72	-0.49	-0.02
Shares Outstanding (Basic)	111	104	100	100
Shares Outstanding (Diluted)	111	104	100	100
Shares Change (YoY)	6.42%	4.42%	-	-
EPS (Basic)	0.01	-0.01	-0.00	-
EPS (Diluted)	0.01	-0.01	-0.00	-
Free Cash Flow	0.12	-0.32	-0.47	-1.86
Free Cash Flow Per Share	0.00	-0.00	-0.01	-0.02
Gross Margin	86.84%	74.21%	-	69.83%
Operating Margin	25.54%	-778.78%	-	6.48%
Profit Margin	93.35%	-1350.92%	-	-10.00%
Free Cash Flow Margin	13.29%	-602.91%	-	-922.13%
EBITDA	0.28	-0.39	0.03	0.05
EBITDA Margin	31.97%	-	-	26.25%
D&A For EBITDA	0.06	0.02	0.15	0.04
EBIT	0.23	-0.42	-0.12	0.01
EBIT Margin	25.54%	-	-	6.48%
Revenue as Reported	0.88	0.05	-	0.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.